Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome

被引:26
|
作者
Goswami, Meghali [1 ]
Duvic, Madeleine [1 ]
Dougherty, Alexis [1 ]
Ni, Xiao [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
关键词
c-myc; mycosis fungoides; p53; Sezary syndrome; Twist; T-CELL LYMPHOMA; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; UP-REGULATION; INTERNATIONAL-SOCIETY; CUTANEOUS-LYMPHOMAS; PROGNOSTIC-FACTORS; DOWN-REGULATION; CANCER; STAT3;
D O I
10.1111/j.1600-0560.2012.01883.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The mechanisms of tumor progression in mycosis fungoides (MF) and Sezary syndrome (SS) are poorly understood. Twist, a transcription factor, is thought to promote solid tumor progression by blocking p53 and inhibiting c-myc-induced apoptosis. Whether Twist expression is correlated to MF/SS stages remains unknown. Methods: Twist, c-myc and p53 proteins in 68 MF/SS lesions across all T stages were examined by immunohistochemistry, and mRNA levels in peripheral blood CD4+ T-cells from SS patients were measured by real-time quantitative polymerase chain reaction. Results: Positive staining for Twist was found in 12.5% (2/16) of T1 and 33.3% (7/21) of T2 early stage patches/plaques compared to 50.0% (9/18) of T3 tumors and 84.6% (11/13) of T4 erythroderma. Most T4 erythroderma were positive for Twist in dermal lymphocytes, with the strongest staining. Positive staining for c-myc was higher in T3/T4 lesions (29/31, 93.5%) than T1/T2 lesions (25/37, 67.6%, p < 0.05), with strongest staining in T3 tumors. Aberrant p53 expression was more common in T3/T4 lesions (8/31, 25.8%) than in T1/T2 lesions (2/37, 5.4%, p < 0.05). Twist mRNA was detected in all CD4+ T cells from SS patients but not in normal donors. Conclusions: Increased Twist protein expression in advanced MF/SS lesions suggests that Twist expression may correlate with MF/SS stages.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 50 条
  • [21] Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sezary syndrome
    Jothishankar, Balaji
    Almazan, Tim
    Kim, Youn
    Liauw, Stanley
    Smith, Sonali
    Kline, Justin
    Abdulla, Farah
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (02) : 377 - 379
  • [22] MYCOSIS-FUNGOIDES AND SEZARY SYNDROME
    SOUTEYRAND, P
    THIVOLET, J
    PATHOLOGY RESEARCH AND PRACTICE, 1981, 171 (02) : 240 - 261
  • [23] Mycosis Fungoides and Sezary Syndrome: An Update
    Larocca, Cecilia
    Kupper, Thomas
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 33 (01) : 103 - +
  • [24] The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View
    Giordano, Antonio
    Pagano, Livio
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2022, 14
  • [25] Diagnostics in mycosis fungoides and Sezary syndrome
    Olek-Hrab, Karolina
    Silny, Wojciech
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2014, 19 (02) : 72 - 76
  • [26] Mycosis fungoides and Sezary Syndrome: An update
    Kim E.J.
    Lin J.
    Junkins-Hopkins J.M.
    Vittorio C.C.
    Rook A.H.
    Current Oncology Reports, 2006, 8 (5) : 376 - 386
  • [27] SEZARY SYNDROME (MYCOSIS FUNGOIDES VARIANT)
    COLBURN, HL
    BEGGS, DW
    ARCHIVES OF DERMATOLOGY, 1965, 91 (06) : 682 - &
  • [28] Treatment of mycosis fungoides and Sezary syndrome
    Nicolay, J. P.
    Assaf, C.
    HAUTARZT, 2017, 68 (09): : 702 - 710
  • [29] Programmed death 1 expression in mycosis fungoides and Sezary syndrome
    Wada, David
    Comfere, Nneka
    Harrington, Susan
    Ryan, Wilcox
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB114 - AB114
  • [30] Increased serum immunoglobulin levels are common in mycosis fungoides and Sezary syndrome
    Talpur, R
    Lifshitz, O
    Breuer-McHam, J
    Duvic, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (05) : 685 - 691